Read Article

Supporting international business matching, LSMIP propritizes "Speed" and "Accuracy" in out service.
Please be noted that contents are in English/Japanese, translated on a request basis from authors/members.
国際間のビジネス・マッチングを促進するため、LSMIPでは情報発信の迅速性・正確性を重視しております。
コンテンツは各言語(英語、日本語)でお読みいただけますが、必要に応じて翻訳する場合があります。

Overview

0

[Yakuji Nippo]Discontinues Development, Unable to Acquire Designation as Orphan Drugs – Demand for Designation Criteria Equivalent to Europe and U.S.

In the questionnaire investigation conducted on 59 member companies by the pharmaceutical affairs committee of the Japan Pharmaceutical Manufacturers Association, ...
  • Target market
    Japan
  • Business category
    Pharmaceutical, Biopharmaceutical, Regerative medicine, Medical device, Digital health, Others
  • Business function
    Marketing >
  • Keyword
  • Author
    "LSMIP Editorial Office" of "CM Plus Corporation"
  • Availability
    Membership

Detail


株式会社薬事日報社から許諾を受けて、株式会社シーエムプラスが英語に翻訳しております。
オリジナルの正式言語は日本語であり、内容および解釈については日本語が優先されます。
With permission from Yakuji Nippo, Limited, CM Plus Corporation translated into English.
The original article is authored in Japanese, and the Japanese shall prevail in meaning in terms of content and interpretation.

 

【Pharmaceutical Affairs Committee of the Japan Pharmaceutical Manufacturers Association】 
Discontinues Development, Unable to Acquire Designation as Orphan Drugs – Demand for Designation Criteria Equivalent to Europe and U.S.

December 09th, 2020

In the questionnaire investigation conducted on 59 member companies by the pharmaceutical affairs committee of the Japan Pharmaceutical Manufacturers Association, it became apparent that in Japan there have been cases where development was discontinued, such as abandonment of efficacy addition, because of failure to acquire designation as orphan drugs.  In Japan, there have been many cases where the drugs were not designated because the data showing efficaciousness and safety significantly higher than those of existing drugs did not exist at the time of consulting.  On the other hand, in Europe and U.S., they found that there was a tendency to give designations widely at an early stage based on the data from Phase I trial and Phase II trial.  The committee is demanding the regulatory authority to make the designation criteria to be equivalent to that of Europe and U.S.
 

(Continue to the next)


For this translated article in English, CM Plus Corporation shall have the copyright.
Unauthorized reproduction of posted articles, photos, diagrams, etc. is prohibited.
Copyright © 2020 LSMIP office / CM Plus Singapore Pte. Ltd.

Comments (Require approval)

What information are you looking for in articles?
Let us help you to find out the articles for your business requirements!
Like many other companies, we use cookies and other technologies, some of which are essential to make our website work. By clicking Accept or continuing to use our site, you agree to use these cookies and other technologies. To learn more, check out our privacy policy.
Accept